Therapeutic Strategies for the Management of HCV/HIV co- infection

$441,974ZIAFY2012AINIH

National Institute Of Allergy And Infectious Diseases

Investigators

Linked publications & trials

Paper 25383134 Paper 25309617 Paper 25117132 Paper 24983321 Paper 24856902 Paper 24782267 Paper 24700849 Paper 24367041 Paper 24171456 Paper 24166150 Paper 23982366 Paper 23838779 Paper 23818847 Paper 23701022 Paper 23593207 Paper 23418453 Paper 23378283 Paper 23259453 Paper 23121362 Paper 23105947 Paper 22825812 Paper 22733887 Paper 22728749 Paper 22585729 Paper 22577869 Paper 22454462 Paper 22331604 Paper 22239502 Paper 21957313 Paper 21921725 Paper 21917890 Paper 21771990 Paper 21640198 Paper 21593619 Paper 21336381 Paper 20837780 Paper 20684729 Paper 20677940 Paper 20639253 Paper 20420510 Paper 20235668 Paper 20101190 Paper 19898214 Paper 19797971 Paper 19795986 Paper 19788693 Paper 19594300 Paper 19551908 Paper 19519227 Paper 18614866 Paper 18184077 Paper 17721093 Paper 17558334 Paper 17520017 Paper 17147494 Paper 17053062 Paper 16987047 Paper 16552065 Paper 16544259 Paper 16393999 Paper 15817955 Paper 15316341 Paper 15249574 Paper 15090813 Paper 15002084 Paper 14726376 Paper 14679460 Paper 14532178 Paper 12898439 Paper 12819518 Paper 12684920 Paper 12093241 Paper 11734232 Paper 11286539 Paper 11095734 Paper 11004259 Paper 10985306 Paper 10915072 Paper 10898693 Paper 10889591 Paper 10887107 Paper 10878387 Paper 10694578 Paper 10671334

Abstract

Recent advances in the treatment and monitoring of HIV-1 infection have substantially diminished HIV-associated illness and mortality; however the hepatitis C has emerged as a major co morbidity among HIV-infected patients. We are conducting studies that: (1) evaluate novel therapeutic strategies in the management of HCV-infected individuals, and (2) identify the host response characteristics that predict HCV response to existing treatment and aid in developing better future therapies. This past year, we were able to (1) determine the safety, tolerability and effectiveness of a novel regimen including twice monthly Albumin-Interferon alpha 2b along with Ribavirin to treat Hepatitis C in HIV co-infected subjects; (2) demonstrate the distinct influence of ongoing HIV replication on host immune activation profiles in Hepatitis C infected subjects; (3) demonstrate the effect of race, host genetics and baseline immune status (CD4+ T cell count) on response rates to HCV and adverse events using the pegylated Interferon-alpha and Ribavirin

View original record on NIH RePORTER →